Artelo Biosciences, Inc. Stock

ARTL

US04301G7060

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-13 EDT			5-day change	1st Jan Change
0.7587 ^USD	+3.51%		+0.84%	-79.27%

08-12	Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-10	Artelo Biosciences, Inc. Enrolls First Patient in Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma	CI

Valuation: Artelo Biosciences, Inc.

Market Cap	2.64M 2.29M 2.15M 1.96M 3.69M 252M 3.75M 25.3M 9.88M 126M 9.93M 9.71M 421M	P/E 2024	-0.35x	P/E 2025	-0.1x
Enterprise Value	2.72M 2.36M 2.21M 2.02M 3.8M 260M 3.86M 26.05M 10.17M 130M 10.22M 10M 434M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	92.16%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Chart: Artelo Biosciences, Inc.

Dynamic Chart

Latest news : Artelo Biosciences, Inc.

08-12	Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-10	Artelo Biosciences, Inc. Enrolls First Patient in Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma	CI
07-16	Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions	CI
07-16	Artelo Biosciences Says New Data Shows ART26.12 Reduces Osteoarthritis Pain	MT
07-13	Artelo Says ART27.13 Decreases Neuropathic Pain-linked Behaviors in Animals Treated With Paclitaxel	MT
07-13	Artelo Biosciences Announces Positive Results With ART27.13 In A Nonclinical Model Of Paclitaxel-Induced Peripheral Neuropathy	CI
07-01	Artelo Biosciences Announces New Data Supporting ART26.12 As A Potential First-In-Class Therapy For Chronic Pain Associated With Spinal Cord Injury	CI
06-30	Artelo Biosciences Presents Evidence for A Common Lipid-Signaling Link Across Multiple Potential Indications for Its Fabp5 Inhibitor Platform At Icrs 2026	CI
06-29	Artelo Biosciences Presents Clinical And Biomarker Data Supportive Of The Development Of ART26.12 And Follow-On FABP5 Inhibitors	CI
06-10	Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated With Clinical Development Success	CI
05-27	Top Premarket Decliners	MT
05-26	Artelo Biosciences to offer up to $6.53 million in common stock via H.C. Wainwright	RE
05-26	Top Premarket Gainers	MT

More news

Analysts' recommendations: Artelo Biosciences, Inc.

11-19	Maxim Downgrades Artelo Biosciences to Hold From Buy	MT
25-10-15	Artelo Biosciences, Inc. Announces Expanded Clinical Data to Be Presented on Both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit	CI
22-08-12	HC Wainwright Lowers Price Target for Artelo Biosciences to $55 From $60, Maintains Buy Rating	MT
21-11-01	HC Wainwright Starts Artelo Biosciences at Buy With $4 Price Target	MT
21-02-12	Artelo Biosciences : Ladenburg Thalmann Starts Artelo Biosciences at Buy with $7 Price Target	MT

More recommendations

Press Releases: Artelo Biosciences, Inc.

08-13	Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results	AQ
08-10	Artelo Announces Enrollment of First Patient in a Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma	AQ
07-23	New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy, Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition	AQ
07-22	New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition	AQ
07-16	Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions	AQ

More press releases

Managers and Directors: Artelo Biosciences, Inc.

Manager	Title	Age	Since
Gregory Gorgas CEO	Chief Executive Officer	63	2017-04-02
Mark Spring DFI	Director of Finance/CFO	67	2024-11-30
Andy Yates CTO	Chief Tech/Sci/R&D Officer	-	2020-12-31

Director	Title	Age	Since
Gregory Gorgas BRD	Director/Board Member	63	2017-04-02
Connie Matsui CHM	Chairman	72	2017-05-01
Steven Kelly BRD	Director/Board Member	61	2017-05-01

More insiders

Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-08-13	US$0.7587	+3.51%	265,368
26-08-12	US$0.7330	-1.57%	84,563
26-08-11	US$0.7447	+5.62%	95,462
26-08-10	US$0.7051	-2.21%	165,779
26-08-07	US$0.7210	-4.17%	117,342

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Stocks
ARTL Stock

The best tools reserved for subscribers to boost the performance of your investments!

1 day	+3.51%
1 week	+0.84%
Current month	-1.47%
1 month	-27.74%
3 months	-67.16%
6 months	-78.92%
Current year	-79.27%

1 week	0.71	0.84
1 month	0.71	1.24
Current year	0.71	19.91
1 year	0.71	31.65
3 years	0.71	85.8
5 years	0.71	356.4
10 years	0.71	5,832

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/17/26	Steven Kelly	Free	Director	136	0.0039%
7/17/26	Tamara Favorito	Free	Director	136	0.0039%
7/17/26	Robert Emanuele	Free	Director	136	0.0039%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARTELO BIOSCIENCES, INC.	+3.51%	+0.84%	-97.50%	-97.80%	2.64M
WUXI APPTEC CO., LTD.	+2.07%	+13.76%	+65.44%	+106.53%	71.56B
ARGENX SE	-0.87%	+0.08%	+36.96%	+65.91%	54.43B
INSMED INCORPORATED	-4.50%	-4.69%	+2.82%	+463.22%	27.59B
WUXI BIOLOGICS (CAYMAN) INC.	-2.58%	-2.62%	+44.91%	+4.96%	23.91B
BIONTECH SE	-0.67%	+1.02%	-18.32%	-13.84%	23.14B
GENMAB A/S	-0.59%	+7.88%	+40.87%	-20.56%	18.65B
PHARMAESSENTIA CORPORATION	+0.35%	+12.02%	+257.19%	+466.50%	18.64B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.28%	-4.63%	+18.66%	+604.79%	16.01B
EXELIXIS, INC.	+0.46%	-3.05%	+31.49%	+135.18%	12.54B
Average	-0.46%	+3.74%	+38.25%	+171.49%	26.65B
Weighted average by Cap.	-0.47%	+3.63%	+51.31%	+163.16%

	2024	2025
Net sales	-	-
Net income	-9.83M -8.52M -7.98M -7.28M -13.7M -938M -13.92M -94.01M -36.7M -469M -36.89M -36.09M -1.57B	-12.88M -11.16M -10.46M -9.54M -17.95M -1.23B -18.24M -123M -48.11M -615M -48.35M -47.3M -2.05B
Net Debt	-2.23M -1.94M -1.82M -1.66M -3.11M -213M -3.16M -21.37M -8.34M -107M -8.39M -8.21M -356M	78K 67.61K 63.38K 57.79K 109K 7.44M 110K 746K 291K 3.73M 293K 286K 12.43M

Artelo Biosciences, Inc. Stock

Stocks

ARTL

US04301G7060

Biotechnology & Medical Research

Valuation: Artelo Biosciences, Inc.

Chart: Artelo Biosciences, Inc.

Latest news : Artelo Biosciences, Inc.

Analysts' recommendations: Artelo Biosciences, Inc.

Press Releases: Artelo Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Artelo Biosciences, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise